BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35425962)

  • 1. Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.
    Yousefi M; Boross G; Weiss C; Murray CW; Hebert JD; Cai H; Ashkin EL; Karmakar S; Andrejka L; Chen L; Wang M; Tsai MK; Lin WY; Li C; Yakhchalian P; Colón CI; Chew SK; Chu P; Swanton C; Kunder CA; Petrov DA; Winslow MM
    Cancer Res; 2022 Apr; 82(8):1589-1602. PubMed ID: 35425962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Tyrosine Phosphatase Non-Receptor 11 (
    Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
    Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
    Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
    J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
    Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
    J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA; Khuri FR; Garon EB; Ramalingam SS
    Cancer; 2016 Mar; 122(5):766-72. PubMed ID: 26695526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
    Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
    J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Lee YS; Lee JY; Song SH; Kim DM; Lee JW; Chi XZ; Ito Y; Bae SC
    Mol Cells; 2020 Oct; 43(10):889-897. PubMed ID: 33115981
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular pathogenesis of transplacentally induced mouse lung tumors.
    Miller MS; Leone-Kabler S; Rollins LA; Wessner LL; Fan M; Schaeffer DO; McEntee MF; O'Sullivan MG
    Exp Lung Res; 1998; 24(4):557-77. PubMed ID: 9659583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.
    Unni AM; Lockwood WW; Zejnullahu K; Lee-Lin SQ; Varmus H
    Elife; 2015 Jun; 4():e06907. PubMed ID: 26047463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
    Drosten M; Barbacid M
    J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis.
    Lahtela J; Pradhan B; Närhi K; Hemmes A; Särkioja M; Kovanen PE; Brown A; Verschuren EW
    Dis Model Mech; 2015 Apr; 8(4):393-401. PubMed ID: 25713296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.
    Duan W; Gao L; Kalvala A; Aguila B; Brooks C; Mo X; Ding H; Shilo K; Otterson GA; Villalona-Calero MA
    Int J Cancer; 2019 Nov; 145(9):2418-2426. PubMed ID: 30873587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer.
    Cai H; Chew SK; Li C; Tsai MK; Andrejka L; Murray CW; Hughes NW; Shuldiner EG; Ashkin EL; Tang R; Hung KL; Chen LC; Lee SYC; Yousefi M; Lin WY; Kunder CA; Cong L; McFarland CD; Petrov DA; Swanton C; Winslow MM
    Cancer Discov; 2021 Jul; 11(7):1754-1773. PubMed ID: 33608386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress.
    Hong BJ; Park WY; Kim HR; Moon JW; Lee HY; Park JH; Kim SK; Oh Y; Roe JS; Kim MY
    Cancer Res; 2019 Nov; 79(22):5849-5859. PubMed ID: 31506334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.